Aquestive TherapeuticsAQST
AQST
About: Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Employees: 142
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
59% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 29
50% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 3 (+1) [Q1 2025]
47% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 19
6% more funds holding
Funds holding: 114 [Q4 2024] → 121 (+7) [Q1 2025]
2.82% less ownership
Funds ownership: 47.57% [Q4 2024] → 44.76% (-2.82%) [Q1 2025]
15% less capital invested
Capital invested by funds: $154M [Q4 2024] → $131M (-$23.6M) [Q1 2025]
58% less call options, than puts
Call options by funds: $391K | Put options by funds: $923K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
79%
upside
Avg. target
$8.50
117%
upside
High target
$10
155%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju | 155%upside $10 | Buy Reiterated | 17 Jun 2025 |
Oppenheimer Andreas Argyrides | 79%upside $7 | Outperform Assumed | 2 Jun 2025 |
Financial journalist opinion
Based on 3 articles about AQST published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
WARREN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the promotion of Sherry Korczynski, from Senior Vice President of Sales and Marketing, to Chief Commercial Officer effective July 22, 2025.
Neutral
GlobeNewsWire
2 weeks ago
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
WARREN, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that Health Canada has granted the Company a meeting to discuss Aquestive's planned New Drug Submission (NDS) for Anaphylm™ (epinephrine) Sublingual Film in Canada. In addition, the Company has submitted an initial briefing book to the European Medicines Agency (EMA). The Company plans to submit a Marketing Authorization Application (MAA) to the EMA as soon as possible.
Neutral
GlobeNewsWire
3 weeks ago
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host 1x1 investor meetings on July 9, 2025. The forum will include panels exploring key therapeutic themes across the fields of immunology and inflammation (I&I), and metabolism.
Positive
Seeking Alpha
1 month ago
Aquestive Therapeutics: Updating The Anaphylm Timeline To Approval
Anaphylm's FDA approval process is a major catalyst, with a PDUFA date set for January 31, 2026, and potential AdCom or partnership news ahead. Anaphylm offers a needle-free, orally delivered epinephrine alternative, boasting rapid absorption and strong clinical data, supporting high approval confidence. If approved, Anaphylm could drive significant revenue growth and a potential company rerating, with peak sales estimates up to $1B and substantial upside from current levels.
Neutral
GlobeNewsWire
1 month ago
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
WARREN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two poster presentations highlighting results from the investigational use of Anaphylm™ (epinephrine) Sublingual Film in the treatment of severe allergic reactions, including anaphylaxis, will be presented at the Center for Food Allergy and Asthma Research (CFAAR) Food Allergy Summit , which will be held June 27-29 in Chicago, Ill. The data from these posters was originally presented at the 2025 AAAAI Annual Meeting. If approved by the U.S. Food and Drug Administration (FDA), Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
Positive
Zacks Investment Research
1 month ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Positive
Seeking Alpha
1 month ago
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share
Aquestive Therapeutics' Anaphylm offers a unique, non-injectable epinephrine solution for anaphylaxis, with NDA decision expected imminently. Anaphylm's advantages—wallet portability, rapid onset, and high patient/provider preference—position it to capture significant share of a $2B U.S. market. My risk-adjusted DCF analysis values AQST at $5/share ( at just 10% market share), indicating the stock is undervalued at current levels.
Neutral
Seeking Alpha
2 months ago
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call Transcript
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Stanley Kristen Kluska - Cantor Fitzgerald Jason Butler - Citizens JMP Raghuram Selvaraju - HC Wainwright Dennis Resnick - Raymond James Nelson Cox - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call.
Neutral
Zacks Investment Research
2 months ago
Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Negative
Zacks Investment Research
2 months ago
Aquestive Therapeutics (AQST) Reports Q1 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
Charts implemented using Lightweight Charts™